We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

EPO Revokes Controversial Patent For Breast Cancer Screening

Law360 (May 19, 2004, 12:00 AM EDT) -- The European Patent Office has revoked U.S. biotechnology company Myriad Genetics’ European patent on a controversial breast cancer genetic test that critics claim is excessively expensive.

The patent covers a test to predict if a woman is at high risk of developing breast cancer by looking for mutations in a gene called BRCA1.

“After a public hearing of all parties to the opposition proceedings against the patent, the division - a panel composed of three patent examiners and a legal expert - concluded that the grounds...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.